H. Lundbeck A/S

H. Lundbeck develops, produces and markets drugs for treating diseases of the central nervous system. Products include antidepressants for the treatment of depression, panic disorder, and prevention of relapse/recurrence. Antipsychotic products for psychotic disorders; schizophrenia, anxiety, restlessness and insomnia; treatment of psychotic disorders; acute psychotic episodes, exacerbation of psychotic disorders. Co.'s products inclue Cipralex®/Lexapro® for the treatment of depression and anxiety; Ebixa® for the treatment of Alzheimer's disease; Azilect® for the treatment of Parkinson's disease; Xenazine®, Sabril®, Saphris® Sycrest®, Onfi, and other.
  • TickerLUN
  • ISINDK0010287234
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

Expert Corporate Governance Service (ECGS)

H.Lundbeck, March 26 2019

In general, Lundbeck is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEM 4.1, it is proposed to re-appoint Mr. Lars Soren Rasmussen as Chairman of  the board of directors. Although he is considered independent, ECGS notes that Mr. Rasmussen is currently chairing the Company's remuneration committee, which is not in accordance with its guidelines. ECGS furthermore notes a lack of female representation (22%) on the board and based on its guidelines the re-election of the chairman of the chairmanship (performing the dutie...

Karen Andersen

Morningstar | Lundbeck's Onfi Sales Deteriorate With Generic Entry but 4Q Results Within Expectations

Narrow-moat Lundbeck reported fourth quarter results mostly in line with our expectations, including about DKK 4.1 billion in revenue contributing to full-year revenue of DKK 18.1 billion (up 8% in local currencies from last year). After making a few minor adjustments, we don't expect a material change to our fair value estimate of DKK 290 per share. U.S.-only Onfi for epilepsy lost orphan drug exclusivity in October 2018, resulting in about a 40% decline in fourth-quarter sales. We expect this to have a significant impact on 2019, projecting a 70% decline in Onfi sales due to aggressive gener...

Karen Andersen

Morningstar | Lundbeck's Onfi Sales Deteriorate With Generic Entry but 4Q Results Within Expectations. See Updated Analyst Note from 05 Feb 2019

Narrow-moat Lundbeck reported fourth quarter results mostly in line with our expectations, including about DKK 4.1 billion in revenue contributing to full-year revenue of DKK 18.1 billion (up 8% in local currencies from last year). After making a few minor adjustments, we don't expect a material change to our fair value estimate of DKK 290 per share. U.S.-only Onfi for epilepsy lost orphan drug exclusivity in October 2018, resulting in about a 40% decline in fourth-quarter sales. We expect this to have a significant impact on 2019, projecting a 70% decline in Onfi sales due to aggressive gener...

Karen Andersen

Lundbeck's Onfi Sales Deteriorate With Generic Entry but 4Q Results Within Expectations

Narrow-moat Lundbeck reported fourth quarter results mostly in line with our expectations, including about DKK 4.1 billion in revenue contributing to full-year revenue of DKK 18.1 billion (up 8% in local currencies from last year). After making a few minor adjustments, we don't expect a material change to our fair value estimate of DKK 290 per share. U.S.-only Onfi for epilepsy lost orphan drug exclusivity in October 2018, resulting in about a 40% decline in fourth-quarter sales. We expect this ...

Rune Majlund Dahl

Lundbeck (Sell, TP: DKK270.00) -

Lundbeck (LUN DC, downgrade to Sell) - (15 pages)

Rune Majlund Dahl

Lundbeck (Hold, TP: DKK290.00) - Guidance of declining growth

Q4 sales beat expectations (c1.3% above our estimate and 0.7% above consensus). The 20.2% EBIT margin was lower than expected (we forecast c20.4%), driven by a lower gross margin and higher R&D spend. The strategic review disappointed in our view with no firm financial targets, apart from 2019 guidance for revenue of DKK16.1bn–16.7bn and EBIT of DKK4.2bn–4.6bn. We see consensus 2019e EPS coming down 1–2% based on the guidance, and see a negative share price reaction of 3%+ today.

Two Directors sold after exercising options/sold 440,000 shares at between 387.660DKK and 394.850DKK.

Two Directors at Lundbeck(H) A S sold after exercising options/sold 440,000 shares at between 387.660DKK and 394.850DKK. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading act...

Christer Magnergård ...
  • Martin Arnell
  • Mattias Holmberg
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Rune Majlund Dahl

Northern Lights

Christer Magnergård ...
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Antti Kansanen
  • Jørgen Lian
  • Niclas Gehin
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northen Lights

Alexander Aukner ...
  • Eivind Sars Veddeng
  • Jesper Ingildsen
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Niclas Gehin
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Håkon Astrup ...
  • Jesper Ingildsen
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Marius Knudssøn
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Paul Harper
  • Rune Majlund Dahl

Northern Lights

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report

Synopsis H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Summary - Detailed information on H. Lundbeck A/S required for business and competitor intelligence needs - A study of the major internal and external factors affecting H. Lundbeck A/S in the form of a SWOT analysis - An in-depth view of the business model of H. Lundbeck A/S including a breakdown and exam...

Expert Corporate Governance Service (ECGS)

H.Lundbeck, March 26 2019

In general, Lundbeck is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEM 4.1, it is proposed to re-appoint Mr. Lars Soren Rasmussen as Chairman of  the board of directors. Although he is considered independent, ECGS notes that Mr. Rasmussen is currently chairing the Company's remuneration committee, which is not in accordance with its guidelines. ECGS furthermore notes a lack of female representation (22%) on the board and based on its guidelines the re-election of the chairman of the chairmanship (performing the dutie...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (RSR...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch